• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
    All News #Library
    Biotech

    Harbour Biomed Reveals 2025 Financials: Global Collaboration

    PR NEWSWIRE

    Kelun-Biotech, Harbour Biomed Get NMPA Nod For SKB575/HBM7575

    PR NEWSWIRE

    Harbour Sails With Solstice In $1.1B Biobucks Deal

    FIERCE BIOTECH

    Harbour Biomed Announces Positive 2025 Profit Alert

    PR NEWSWIRE

    Harbour Collaborates With Lannacheng On Radionuclide Drug

    PR NEWSWIRE BIO

    Evinova China, Harbour Biomed Partner For AI-Driven Drug Develop

    BUSINESSWIRE

    Harbour BioMed Unveils AI HCAb Model for Biologics Discovery

    PR NEWSWIRE

    Harbour Biomed Reports Positive Phase 2 Data For HBM4003

    PR NEWSWIRE

    Harbour Shows Ph II Data on CRC Combo With Tislelizumab at ESMO

    PR NEWSWIRE

    Anti-TSLP Ab HBM9378/WIN378 Starts Global Ph2 Asthma Trial

    PR NEWSWIRE

    Harbour BioMed, Otsuka Partner to Advance BCMAxCD3 T-Cell Engager

    PR NEWSWIRE

    Harbour BioMed Reports Full Year 2024 Financial Results

    PR NEWSWIRE

    Harbour BioMed Launches Élancé For Next-Gen Obesity Therapies

    PR NEWSWIRE

    HBM Alpha Signs Endocrine Therapy Deal, Licenses Novel Therapies

    PR NEWSWIRE

    Harbour BioMed & Insilico Partner For AI-Driven Antibody Discovery

    PR NEWSWIRE

    Kelun-Biotech Licenses SKB378/HBM9378 Anti-TSLP Monoclonal Antibody

    PR NEWSWIRE

    Harbour BioMed Licenses Anti-TSLP Antibody for Immune Diseases

    PR NEWSWIRE

    Harbour BioMed Publishes Phase I Study Results For Porustobart

    PR NEWSWIRE

    Harbour BioMed Presents HBM1020 Clinical Data At ESMO Congress 2024

    PR NEWSWIRE

    Harbour BioMed Resubmits Batoclimab Biologics License For Myasthenia Gravis

    PR NEWSWIRE

    Harbour IND Clearance of Its First ADC Program HBM9033 in Solid Tumors

    PR NEWSWIRE

    Harbour BioMed Announces BLA Acceptance of Batoclimab for Myasthenia Gravis

    PR NEWSWIRE

    Harbour BioMed Announces First Patient Dosed in Phase I Study of HBM1020

    PR NEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.